Literature DB >> 29152786

Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence.

Cosimo Andrea Stamerra1, Paolo Di Giosia1, Paolo Giorgini1, Martina De Feo1, Davide Grassi1, Claudio Ferri1, Amirhossein Sahebkar2,3.   

Abstract

Entities:  

Keywords:  PCSK9 inhibitors; atherosclerosis; lipids; neurocognitive events; statins

Year:  2017        PMID： 29152786     DOI： 10.1002/jnr.24199

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN： 0360-4012            Impact factor:   4.164


× No keyword cloud information.
  1 in total

1.  Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?

Authors:  Nazzareno Cervelli; Giuliano Tocci; Claudio Ferri
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-01-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.